Pancreatic cancer: new approaches to drug therapy

• Published in: International journal of surgery (London, England) Vol. 110; no. 10; pp. 6070 - 6080
• Main Author: Picozzi, Vincent J
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 04.04.2024
• Subjects: Updates Onpancreatic Cancer Treatment
• ISSN: 1743-9159; 1743-9191; 1743-9159
• DOI: 10.1097/JS9.0000000000000877

Outcomes in pancreatic ductal adenocarcinoma (PDAC) remain poor due to a variety of biological, clinical, and societal factors. However, in recent years, PDAC has seen 1) increased precision of initial evaluation, 2) increased emphasis on supportive care, 3) deeper understanding of the translation biology of PDAC, especially as pertains to genomic alterations, and 4) foundational combination chemotherapy clinical trials across all disease stages. These advances have led to a wide range of new approaches to drug therapy for PDAC. Currently available drugs are showing added benefit, both by resequencing them with each other and also with respect to other therapeutic modalities. Molecular strategies are being developed to predict response to known therapeutic agents and to identify others. Additionally, a wide range of new drugs for PDAC are under development, including drugs which inhibit critical molecular pathways, drugs which attempt to capitalize on homologous repair deficiencies, immunotherapeutic approaches, antimetabolic agents, and drugs which attack the extracellular matrix which supports PDAC growth. These new approaches offer the promise of improved survival for future PDAC patients.